LAMP1 and lymphoma: However, it was demonstrated recently that a 24-h-pretreatment with Dasatinib, followed by wash off led to dose-dependent enhancement of NK cell cytokine production, CD107a expression, and cytotoxicity against selected lymphoma and leukemia cell lines (Hassold et al., 2012).